Evidence map›Paper›PMID 41769695›Full record

ArticleFrontiers in pharmacology2026

Resveratrol reduces muscle atrophy and stress pathway activation in a combined disuse-hypoxia-mouse model.

Aziz Ahmad Khan, Sajid Khan Sadozai, Fawad Ali, Nemat Khan, Rizwan Qaisar

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aziz Ahmad KhanDepartment of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan.
Sajid Khan SadozaiDepartment of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan.
Fawad AliDepartment of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan.
Nemat KhanDepartment of Medical Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.
Rizwan QaisarDepartment of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mechanical disuse and hypoxia synergistically worsen muscle atrophy by activating apoptosis, necroptosis, and ER stress pathways. While resveratrol, a natural polyphenol, has shown protective effects in isolated disuse or hypoxia models, its efficacy under combined conditions remains unclear. Methods: Male C57BL/6J mice (4 months old) were assigned to ground control or hindlimb unloading (HU) groups under normoxia (21% O Results: HU-hypoxia significantly reduced muscle mass and function, with upregulation of stress-related genes. Resveratrol showed dose-dependent protection: 20 mg/kg modestly reduced atrophy, while 40 mg/kg nearly preserved muscle mass and strength to control levels under both normoxic and hypoxic conditions. To our knowledge, this is the first study to demonstrate protective effects of resveratrol in a combined HU and hypoxia model of muscle atrophy, accompanied by modulation of apoptosis, necroptosis and ER stress related gene expression. Conclusion: These results suggest that resveratrol may decrease muscle degradation in fast twitch dominant muscles under combined disuse and hypoxia. However, these results are restricted to gastrocnemius muscle in mice, and further investigations in slow twitch muscles and clinical models are required before clinical relevance can be confirmed. These findings support its potential as a therapeutic agent for muscle loss in clinical and spaceflight settings, warranting further translational research.

Indexed as

apoptosisendoplasmic reticulum (ER) stresshindlimb unloadingmuscle atrophymuscle strengthnecroptosisskeletal muscle

Identifiers

PMID41769695
PMCPMC12936514

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.